Enhanced Gi signaling selectively negates β 2-adrenergic receptor (AR)- but not β1-AR-mediated positive inotropic effect in myocytes from failing rat hearts

Circulation

Volumn 108, Issue 13, 2003, Pages 1633-1639

  Xiao, Rui Ping ^a,e   Zhang, Sheng Jun ^a   Chakir, Khalid ^a   Avdonin, Pavel ^a   Zhu, Weizhong ^a   Bond, Richard A ^b   Balke, C William ^c,d   Lakatta, Edward G ^a   Cheng, Heping ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Contractility; Heart failure; Proteins; Receptors, adrenergic, beta

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; FENOTEROL; GUANINE NUCLEOTIDE BINDING PROTEIN; PERTUSSIS TOXIN; PROCATEROL; RECEPTOR SUBTYPE; SALBUTAMOL; ZINTEROL;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILE FORCE; HEMODYNAMICS; IN VITRO STUDY; INOTROPISM; LIGAND BINDING; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; RAT STRAIN; RECEPTOR BINDING; SIGNAL TRANSDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT;

ADRENERGIC BETA-AGONISTS; ANIMALS; CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; CELLS, CULTURED; CHRONIC DISEASE; FENOTEROL; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HETEROTRIMERIC GTP-BINDING PROTEINS; LIGANDS; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOCYTES, CARDIAC; PERTUSSIS TOXIN; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION;

EID: 0141618295     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000087595.17277.73     Document Type: Article

References (45)

1. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205-211.
2. 1-receptor down-regulation in heart failure. Circ Res. 1986;59:297-309.
3. Kiuchi K, Shannon RP, Komamura K, et al. Myocardial β-adrenergic receptor function during the development of pacing-induced heart failure. J Clin Invest. 1993;91:907-914.
4. iα-2 in human end-stage heart failure. Circ Res. 1992;70:688-696.
5. iα in right and left ventricles from patients with ischaemic and dilated cardiomyopathy and predominant left ventricular failure. J Mol Cell Cardiol. 1994;26:133-149.
6. 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol. 1995;47:322-329.
7. 2-adrenergic modulation of cardiac excitation-contraction coupling. Am J Physiol. 1997;273:H1611-H1618.
8. i proteins and its physiological relevance in murine cardiac myocytes. Circ Res. 1999;84:43-52.
9. i. Circ Res. 2000;87:705-709.
10. 2-adrenergic signaling. J Biol Chem. 1999;274:22048-22052.
11. 2+ dynamics, contractility, or phospholamban phosphorylation. J Biol Chem. 1994;269:19151-19156.
12. 2-adrenergic stimulation. Circulation. 1995;92:1612-1618.
13. 2-Adrenergic cAMP signaling is uncoupled from phosphorylation of cytoplasmic proteins in canine heart. Circulation. 1999;99:2458-2465.
14. 2+ current in single rat ventricular cells. Circ Res. 1993;73:286-300.
15. 2-adrenergic responses without changes in inhibitory G proteins or receptor kinases. J Clin Invest. 1998;101:1273-1282.
16. 2-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation. 1999;100:2210-2212.
17. 2-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci USA. 2001;98:1607-1612.
18. i-dependent coupling to phosphatidylinositol 3′-kinase. Circ Res. 2000;87:1172-1179.
19. 2+/calmodulin kinase II. J Clin Invest. 2003;111:617-625.
20. 2-adrenergic stimulation. Circ Res. 2002;91:46-53.
21. 2+ channels. Biophys J. 2000;79:2547-2556.
22. i proteins. Sci STKE. 2001;104:RE15.
23. Litwin SE, Douglas PS, Aurigemma GP, et al. Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy: chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure. Circulation. 1995;91:2642-2654.
24. Bing OH, Brooks WW, Robinson KG, et al. The spontaneously hypertensive rat as a model of the transition from compensated left ventricular hypertrophy to failure. J Mol Cell Cardiol. 1995;27:383-396.
25. 2-adrenergic agonist for use in asthma: pharmacology, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy. 1985;5:109-126.
26. s or phosphorylating proteins. J Mol Cell Cardiol. 1993;31:1185-1201.
27. Brown LA, Harding SE. The effect of pertussis toxin on β-adrenoceptor responses in isolated cardiac myocytes from noradrenaline-treated guinea-pigs and patients with cardiac failure. Br J Pharmacol. 1992;106:115-122.
28. Koch WJ, Rockman HA, Samama P, et al. Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a β ARK inhibitor. Science. 1995;268:1350-1353.
29. 1-adrenergic receptors in the failing human heart. Circulation. 1993;87:454-463.
30. Anderson KM, Eckhart AD, Willette RN, et al. The myocardial β-adrenergic system in spontaneously hypertensive heart failure (SHF) rats. Hypertension. 1999;33:402-407.
31. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
32. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically falling heart: a new era in the treatment of heart failure. Circulation. 1996;94:2285-2296.
33. 1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA. 1999;96:7059-7064.
34. 1-adrenergic receptor in transgenic mice. J Mol Cell Cardiol. 2000;32:817-830.
35. 2-adrenergic receptor. Science. 1994;264:582-586.
36. 2-adrenergic receptors differentially affect cardiac hypertrophy and function in Gαq-overexpressing mice. Proc Natl Acad Sci USA. 1999;96:6400-6405.
37. 2-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation. 2000;101:1707-1714.
38. 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci USA. 1996;93:10483-10488.
39. 2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest. 1998;102:1534-1539.
40. Ostrom RS, Gregorian C, Drenan RM, et al. Receptor number and caveolar co-localization determine receptor coupling efficiency to adenylyl cyclase. J Biol Chem. 2001;276:42063-42069.
41. Rybin VO, Xu X, Lisanti MP, et al. Differential targeting of β-adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolac: a mechanism to functionally regulate the cAMP signaling pathway. J Biol Chem. 2000;275:41447-41457.
42. Seifert R, Wenzel-Seifert K, Gether U, et al. Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations. J Pharmacol Exp Ther. 2001;297:1218-1226.
43. 2+ current in mouse ventricular myocytes. Mol Pharmacol. 1999;56:485-493.
44. 2AR in myocytes from failing human heart. Circulation. 2002;105:2497-2503.
45. Kenakin T. Agonist-receptor efficacy, II: agonist trafficking of receptor signals. Trends Pharmacol Sci. 1995;16:232-238.